Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Lenalidomide may reduce risk of progression from SMM to MM

Publish date:: May 16, 2019

Key clinical point: Lenalidomide can reduce the risk of progression from smoldering multiple myeloma to multiple myeloma.

Major finding: At 3 years, the rate of progression-free survival was 91% in patients with smoldering multiple myeloma who were randomized to lenalidomide and 66% in those randomized to observation.

Study details: Phase 2/3 trial of 226 patients with intermediate- or high-risk smoldering multiple myeloma.

Disclosures: The National Institutes of Health funded the trial. The lead author has relationships with AbbVie, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen Oncology, Juno Therapeutics, Merck, Novartis, and Takeda.

Citation:

Lonial S et al. ASCO 2019. Abstract 8001.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Lymphoma & Plasma Cell Disorders

Caregiver burden of outpatient ASCT for multiple myeloma comparable with inpatient transplant,

Four-item prognostic index predicts survival in adult Burkitt lymphoma,

Study found dual-targeted CAR T highly active against relapsed/refractory multiple myeloma,

Phase 1 study shows feasibility, safety, efficacy of STAR T cells for ALL,

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,